[Neuroleptic malignant syndrome].
Nishijima
Koichi
K
Department of Psychiatry, Jichi Medical School.
D014150:Antipsychotic Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000494:pharmacology; D001971:Bromocriptine / Q000494:pharmacology / Q000627:therapeutic use; D003620:Dantrolene / Q000494:pharmacology / Q000627:therapeutic use; D003937:Diagnosis, Differential; D003975:Diazepam / Q000627:therapeutic use; D065127:Dopamine D2 Receptor Antagonists; D004565:Electroconvulsive Therapy; D005440:Fluid Therapy; D006801:Humans; D009125:Muscle Relaxants, Central / Q000494:pharmacology / Q000627:therapeutic use; D009459:Neuroleptic Malignant Syndrome / Q000175:diagnosis / Q000209:etiology / Q000517:prevention & control / Q000628:therapy; D017448:Receptors, Dopamine D2 / Q000819:agonists; D012015:Reference Standards; D055502:Secondary Prevention
D014150:Antipsychotic Agents; D065127:Dopamine D2 Receptor Antagonists; D009125:Muscle Relaxants, Central; D017448:Receptors, Dopamine D2; D001971:Bromocriptine; D003620:Dantrolene; D003975:Diazepam